Rosiglitazone and pioglitazone: Two new thiazolidinediones

Practical Diabetes International

Volumn 17, Issue 5, 2000, Pages 135-137

  Bailey, Clifford J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; FATTY ACID; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

DIABETES CONTROL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; EDEMA; EDITORIAL; FLUID RETENTION; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN SENSITIVITY; LIVER CELL DAMAGE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 0033848586     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/1528-252X(200007/08)17:5<135::AID-PDI92>3.0.CO;2-O     Document Type: Editorial

References (25)

1. Thiazolidinediones: A new class of antidiabetic drugs
2. Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetes genes
3. Pathophysiology of insulin resistance in human disease
4. Cardiovascular risk in type 2 diabetes
5. Insulin resistance and antidiabetic drugs
6. Rosiglitazone (BRL49653) monotherapy has significant glucose-lowering effect in type 2 diabetic patients
7. The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes
8. Low-dose rosiglitazone (RSG) provides additional glycemic control when combined with sulfonylureas in type 2 diabetes (T2D)
9. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes
10. Once-daily rosiglitazone (RSG) in combination with metformin (MET) effectively reduces hyperglycemia in patients with type 2 diabetes
11. Combination therapy with pioglitazone and metformin in patients with type 2 diabetes
12. Rosiglitazone (RSG) improves glycemic control in poorly controlled, insulin-treated type 2 diabetes (T2D)
13. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes
14. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week randomized, placebo controlled study
15. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes
16. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients
17. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial
18. The rise and fall of troglitazone
19. Hepatic failure in a patient taking rosiglitazone
20. Hepatocellular injury in a patient receiving rosiglitazone. A case report
21. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor
22. PPARγ. The ultimate thrifty gene
23. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49)